121 related articles for article (PubMed ID: 2143744)
1. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
[TBL] [Abstract][Full Text] [Related]
2. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
[TBL] [Abstract][Full Text] [Related]
3. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis.
Fontenay-Roupie M; Dupuy E; Berrou E; Tobelem G; Bryckaert M
Blood; 1995 Jun; 85(11):3229-38. PubMed ID: 7756654
[TBL] [Abstract][Full Text] [Related]
4. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease.
Rueda F; Piñol G; Marti F; Pujol-Moix N
Acta Haematol; 1991; 85(1):12-5. PubMed ID: 1826402
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease.
Bernabei PA; Arcangeli A; Casini M; Grossi A; Padovani R; Rossi Ferrini P
Br J Haematol; 1986 Jun; 63(2):353-7. PubMed ID: 3755056
[TBL] [Abstract][Full Text] [Related]
7. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
[TBL] [Abstract][Full Text] [Related]
8. Platelet acquired defect in PDGF and beta thromboglobulin content in hairy cell leukaemia: improvement after interferon therapy.
Dupuy E; Sigaux F; Bryckaert MC; Tobelem G; Castaigne S; Flandrin G; Degos L; Caen JP
Br J Haematol; 1987 Jan; 65(1):107-10. PubMed ID: 2949773
[TBL] [Abstract][Full Text] [Related]
9. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
10. [Role of PDGF on myeloproliferative disorders].
Kimura A; Katoh O; Kuramoto A
Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
[No Abstract] [Full Text] [Related]
11. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
Kimura A; Katoh O; Kuramoto A
Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
14. Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes.
Gruber R; Varga F; Fischer MB; Watzek G
Clin Oral Implants Res; 2002 Oct; 13(5):529-35. PubMed ID: 12453131
[TBL] [Abstract][Full Text] [Related]
15. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
16. [Role of growth factors of platelets (PDGF, TGF-beta, EGF) in the pathogenesis of myelofibrosis].
Kimura A; Katoh O; Kuramoto A
Rinsho Byori; 1989 Apr; Spec No 81():1-8. PubMed ID: 2787864
[No Abstract] [Full Text] [Related]
17. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
18. A reversible defect of platelet PDGF content in myeloproliferative disorders.
Baglin TP; Price SM; Boughton BJ
Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
[TBL] [Abstract][Full Text] [Related]
19. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
Katoh O; Kimura A; Itoh T; Kuramoto A
Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
Yonekura S
Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
[No Abstract] [Full Text] [Related]
[Next] [New Search]